These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38030811)

  • 1. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR.
    Bapat J; Yamamoto TM; Woodruff ER; Qamar L; Mikeska RG; Aird KM; Watson ZL; Brubaker LW; Bitler BG
    Cancer Gene Ther; 2024 Feb; 31(2):300-310. PubMed ID: 38030811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 3. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells.
    Reavis HD; Gysler SM; McKenney GB; Knarr M; Lusk HJ; Rawat P; Rendulich HS; Mitchell MA; Berger DS; Moon JS; Ryu S; Mainigi M; Iwanicki MP; Hoon DS; Sanchez LM; Drapkin R
    JCI Insight; 2024 Mar; 9(5):. PubMed ID: 38271085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression.
    Sawyer BT; Qamar L; Yamamoto TM; McMellen A; Watson ZL; Richer JK; Behbakht K; Schlaepfer IR; Bitler BG
    Mol Cancer Res; 2020 Jul; 18(7):1088-1098. PubMed ID: 32198139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
    Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
    Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
    Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
    Dahl ES; Buj R; Leon KE; Newell JM; Imamura Y; Bitler BG; Snyder NW; Aird KM
    Mol Cancer Res; 2019 Aug; 17(8):1710-1720. PubMed ID: 31110157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
    Wang Z; Yang L; Su X; Wu X; Su R
    J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
    Yoon JY; Chapel DB; Goebel E; Qian X; Mito JK; Horowitz NS; Miron A; Soong TR; Xian W; Crum CP
    J Pathol; 2022 Jul; 257(3):255-261. PubMed ID: 35238033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the molecular evolution of extrauterine high grade serous carcinoma.
    Beirne JP; McArt DG; Roddy A; McDermott C; Ferris J; Buckley NE; Coulter P; McCabe N; Eddie SL; Dunne PD; O'Reilly P; Gilmore A; Feeney L; Ewing DL; Drapkin RI; Salto-Tellez M; Kennedy RD; Harley IJG; McCluggage WG; Mullan PB
    Gynecol Oncol; 2019 Nov; 155(2):305-317. PubMed ID: 31493898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium.
    Wang KH; Chu SC; Chu TY
    Oncotarget; 2017 Sep; 8(37):61133-61145. PubMed ID: 28977852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
    Price JC; Azizi E; Naiche LA; Parvani JG; Shukla P; Kim S; Slack-Davis JK; Pe'er D; Kitajewski JK
    PLoS One; 2020; 15(6):e0233962. PubMed ID: 32525899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics.
    Konishi I; Abiko K; Hayashi T; Yamanoi K; Murakami R; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M;
    J Gynecol Oncol; 2022 Sep; 33(5):e83. PubMed ID: 36032027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
    Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
    Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.
    Corkery DP; Clarke LE; Gebremeskel S; Salsman J; Pinder J; Le Page C; Meunier L; Xu Z; Mes-Masson AM; Berman JN; Johnston B; Dellaire G
    Oncogene; 2018 Jan; 37(2):174-184. PubMed ID: 28892043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.